Nova Pharmaceutical Corporation

Baltimore, MD 21224

SBIR Award Summary

Total Number of Awards 14
Total Value of Awards $0.0
First Award Date 09/23/85
Most Recent Award Date 09/01/91

Key Personnel

Last Name Name Awards Contact
Steranka Larry R Steranka 1
Kaplita Paul V Kaplita 1
Abreu Mary E. Abreu 3
Ferkany John W Ferkany 3
Farmer Stephen G Farmer 1
U'Prichard David C U'Prichard 1
Pontecorvo Michael J Pontecorvo 1
Sweetnam Paul M Sweetnam 1
Karbon Edward W Karbon 2

14 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/91 - 02/29/92

Stroke is the most prominent CNS disorder in the United States as well as the leading cause of disability and the third leading cause of death. However, there are no effective treatments available to prevent or reduce neuronal damage resulting from stroke or other forms of cerebral ischemia. Epilepsy is the second most prominent CNS disorder, y...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/91 - 08/31/92

Substantial evidence has accumulated from basic science and clinical studies implicating Corticotropin-releasing factor (CRF) as a physiological or pathophysiological mediator of stress responses of stress-induced disorders. Therefore, it has been hypothesized that a centrally-active CRF antagonist would represent a novel approach for treating ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/91 - 08/31/91

Dopamine (D2) receptor antagonists such as haloperidol and chlorpromazine are most commonly used to treat schizophrenia. However, both acute and chronic administration of these drugs can result in the appearance of extrapyramidal side effects (EPS) which, like the therapeutic effects of these drugs, results from blockade of D2 receptors. Theref...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/91 - 09/30/91

Endothelin-1 (ET-1), a 21 amino acid peptide, acting at specific receptors in vascular tissues has been demonstrated to initiate such physiological responses as: decreases/increases in systemic arterial pressure, alterations in local blood distribution, renal function (i.e. formation and composition of urine, release of circulating hormones), a...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/90 - 08/31/91

Substantial evidence has accumulated from basic science and clinical studies implicating Corticotropin-releasing factor (CRF) as a physiological or pathophysiological mediator of stress responses of stress-induced disorders. Therefore, it has been hypothesized that a centrally-active CRF antagonist would represent a novel approach for treating ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/90 - 12/31/90

There currently exists no effective prophylactic or post-hoc pharmacotherapy for minimizing ischemia-induced neuronal damage. More than one million people in America are believed to suffer neuronal damage and physical and cognitive impairments as a consequence of ischemia associated with chronic cerebrovascular disease or acute cardiac arrest. ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/89 - 06/30/90

Bradykinin (BK), synthesized following many pathological insults, causes smooth muscle contraction, increased vascular permeability and stimulation of neuronal pain receptors, actions generally mediated through B2 receptors. In some animal disease models, there appears in vascular smooth muscle a different receptor, on which des-Arg9-BK, normal...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/88 - 02/28/89

The search for a pharmacological agent that will facilitate weight reduction remains as one of the most challenging areas of drug development. Animal and human data provide sound evidence that body weight is regulated around a physiological "set point," and to date those therapeutic approaches that have attempted to alter an established set poi...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/88 - 03/31/89

Substantial evidence indicates that excitatory amino acid (EAA) neurotransmission plays a role in the pathophysiology of epilepsy, neurodegenerative disorders and the neuronal damage that occurs following hypoxic or ischemic CNS insult. Of the three recognized EAA recognized EAA receptor subtypes (quisqualate, kainate and N- methyl-D-aspartate:...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/88 - 12/31/88

Corticotropin-releasing factor (CRF), a 41-amino acid peptide, acting at specific receptors in the brain and pituitary has been demonstrated to initiate behavioral, physiological and neuroendocrine responses that mimic the response to stress in animals. In addition to its physiological role in mediating stress, recent clinical studies have prov...

Load More